Browse studies, page 717
Page 717 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial International journal of molecular sciences, 2026
- Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India Diabetes, obesity & metabolism, 2025
- Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW Cardiovascular diabetology, 2025
- Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis Medicine, 2025
- Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study Diabetes, obesity & metabolism, 2025
- Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025
- Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial Biomolecules, 2025
- Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet Eating and weight disorders : EWD, 2024
- Impact of GPT-4-Generated Discharge Letters on Patients' Medical Comprehension: Prospective Crossover Study Journal of medical Internet research, 2026
- Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs Diabetes & metabolism journal, 2026
- Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026
- Pharmacokinetics and Safety of Fixed-Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects Clinical and translational science, 2025
- suPAR Identifies Treatment-Resistant Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes With Coronary Artery Disease: An Ancillary Analysis of BARI 2D Diabetes care, 2026
- SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2020
- Comparison of safety profile of DPP4 inhibitors with SGLT2 inhibitors in type 2 diabetes mellitus: systematic review International Journal of Basic & Clinical Pharmacology, 2025
- Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review Advances in therapy, 2023
- GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential BMC ophthalmology, 2026
- Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence Frontiers in endocrinology, 2023
- Impact of diabetes mellitus type two on incidence and progression of Parkinson's disease: a systematic review of longitudinal patient cohorts Journal of neural transmission (Vienna, Austria : 1996), 2025
- Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review International journal of molecular sciences, 2024
- Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence Journal of endocrinological investigation, 2025
- Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials Frontiers in pharmacology, 2023
- Clinical efficacy of probiotics in the treatment of diabetes kidney disease: a systematic review and meta-analysis Frontiers in microbiology, 2025
- Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19 Endocrine, 2024
- Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety International journal of molecular sciences, 2025
- Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review Diabetes, obesity & metabolism, 2026
- Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis The Cochrane database of systematic reviews, 2025
- Sodium glucose co-transporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis in the emergency peri-operative period: a systematic review Journal of anesthesia, 2025
- Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review European journal of clinical investigation, 2025
- Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK Diabetes Therapy, 2017
- SGLT2 Inhibitors: Risks and Benefits Clinical Cardiology and Cardiovascular Interventions, 2024
- 148-LB: Efficacy and Safety of Adding an Oral Hypoglycemic Agent or a GLP-1 Receptor Agonist to Insulin in Patients with Type 1 Diabetes: A Network Meta-analysis Diabetes, 2019
- SGLT2i Dual Therapy with Metformin (Met) for Type 2 Diabetes Mellitus (T2DM)—Systematic Literature Review and Network Meta-analysis (NMA) Diabetes, 2018
- Type 2 Diabetes Mellitus (T2DM) Patients with Inadequate A1C Control on Metformin (MET) + DPP-4i—A Network Meta-analysis (NMA) of the Efficacy and Safety of SGLT2i, GLP-1 Analogs, and Insulin Diabetes, 2018
- 1233-P: Systematic Literature Review (SLR) and Network Meta-analysis (NMA) of SGLT-1/2 Inhibitors vs. Metformin (MET) as Add-On to Insulin in T1DM Diabetes, 2019
- 2185-PUB: Once-Weekly Semaglutide 1mg vs. Empagliflozin 25mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: A Meta-regression Analysis of Individual Patient Data Diabetes, 2020
- Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis Pakistan Journal of Medical Sciences, 2023
- A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis International journal of molecular sciences, 2023
- Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials BMC medicine, 2023
- Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis Cardiovascular diabetology, 2024
- Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials PloS one, 2022
- Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials Lipids in health and disease, 2024
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes The Cochrane database of systematic reviews, 2025
- Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis BMC endocrine disorders, 2024
- Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis Cardiovascular diabetology, 2024
- The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials Frontiers in endocrinology, 2023
- Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis Frontiers in endocrinology, 2023
- Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan-Meier Curves with Trial Sequential Analysis American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024
- Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis Diabetes & metabolism journal, 2024
- Genetic variations in anti-diabetic drug targets and COPD risk: evidence from mendelian randomization BMC pulmonary medicine, 2024
- Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis Age and ageing, 2024
- Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis European journal of medical research, 2024
- Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes ESC heart failure, 2025
- Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Frontiers in endocrinology, 2023
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Journal of the American Heart Association, 2025
- Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials Cardiovascular diabetology, 2023
- Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis Scientific reports, 2024
- Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis International journal of molecular sciences, 2024
- Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post-Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis Journal of cardiovascular electrophysiology, 2025
- Clinical characteristics and outcomes of diabetes-related ketoacidosis (DKA) in sodium-glucose co-transporter-2 inhibitor (SGLT2i) users with type 2 diabetes Diabetes, obesity & metabolism, 2025
- A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition Obesity reviews : an official journal of the International Association for the Study of Obesity, 2026
- SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025
- Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials BMC women's health, 2025
- Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies Cardiovascular diabetology, 2024
- Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis BMC cardiovascular disorders, 2025
- Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis Journal of diabetes research, 2024
- Novel UV Spectroscopic Methods for Simultaneous Assessment of Empagliflozin, Linagliptin and Metformin in Ternary Mixture Indian Journal of Pharmaceutical Education and Research, 2022
- Development and validation of UV spectrophotometric method for Simultaneous estimation of Empagliflozin and Metformin hydrochloride in bulk drugs Asian Journal of Pharmaceutical Analysis, 2017
- Combining Empagliflozin and Linagliptin with Metformin Reduces HbA1c in Patients with T2DM MD Conference Express, 2014
- Development and validation of RP-HPLC method for Empagliflozin and Metformin HCL Journal of Innovations in Pharmaceutical and Biological Sciences, 2017
- Validated Liquid Chromatographic Method for the Determination of (Canagliflozin, Dapagliflozin or Empagliflozin) and Metformin in the Presence of (1-Cyanoguanidine) Journal of Chromatographic Science, 2019
- Referat – Keine Veränderung der Empagliflozin-Wirkung mit Metformin Diabetologie und Stoffwechsel, 2016
- Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy Life Sciences, 2019
- Effects of empagliflozin, sitagliptin and metformin on omentin 1 and resistin in patients with obesity and type 2 diabetes, a prospective study Scientific Reports, 2026
- Validated RP-hplc method for simultaneousdetermination of canagliflozin, dapagliflozin,empagliflozin and metformin 2018
- Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obesity and Metabolism, 2013
- RP-HPLC method development for simultaneous estimation of empagliflozin, pioglitazone, and metformin in bulk and tablet dosage forms Acta Poloniae Pharmaceutica - Drug Research, 2021
- Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin Journal of Chromatographic Science, 2021
- Comparison of glycemic control using combination of empagliflozin with metformin versus sitagliptin with metformin Genetics and Molecular Research, 2026
- Empagliflozin and metformin combination therapy in Type 2 diabetes mellitus International Journal of Basic & Clinical Pharmacology, 2015
- Mean Centering Method for determination of Empagliflozin and Metformin MARMARA PHARMACEUTCAL JOURNAL, 2017
- LC–MS/MS Determination of Empagliflozin and Metformin Journal of Chromatographic Science, 2017
- Glucometabolic efficacy of the empagliflozin/metformin combination in people with type 1 diabetes and increased cardiovascular risk DiRROS repository (University of Maribor), 2025
- A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes ClinicalTrials.gov · TERMINATED, 2018
- A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy ClinicalTrials.gov · COMPLETED, 2026
- Effectivity of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes ClinicalTrials.gov · COMPLETED, 2024
- A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus ClinicalTrials.gov · COMPLETED, 2023
- A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy ClinicalTrials.gov · COMPLETED, 2024
- Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study) ClinicalTrials.gov · COMPLETED, 2013
- Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets (12.5mg Empagliflozin / 1000mg Metformin HCl) Versus Synjardy® 12.5mg/1000mg Film-coated Tablets (12.5mg Empagliflozin/ 1000mg Metformin HCl) in Healthy Subjects Under Fed Conditions ClinicalTrials.gov · COMPLETED, 2024
- Open-label, Randomized, Two-period Comparative Pharmacokinetics and Bioequivalence Study of Empagliflozin + Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) in Healthy Volunteers Under Fed Conditions ClinicalTrials.gov · COMPLETED, 2025
- Clinical Efficacy and Safety of Glimepiride, Empagliflozin and Sitagliptin With Metformin in Type 2 Diabetes Mellitus: A Double and Triple Drug Therapy ClinicalTrials.gov · COMPLETED, 2025
- First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy ClinicalTrials.gov · COMPLETED, 2023
- Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets in Healthy Subjects Under Fed Conditions ClinicalTrials.gov · COMPLETED, 2025
- A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control ClinicalTrials.gov · COMPLETED, 2013
- Clinical Study Evaluating the Efficacy and Safety of Metformin Versus Empagliflozin for Halting Chronic Kidney Disease Progression ClinicalTrials.gov · COMPLETED, 2024
- Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, Two-way Crossover Study ClinicalTrials.gov · COMPLETED, 2014
- A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients ClinicalTrials.gov · COMPLETED
- Relative Bioavailability of Both BI 10773 and Metformin After Coadministration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Metformin (1000 mg b.i.d.) Alone to Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study) ClinicalTrials.gov · COMPLETED
- Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Empagliflozin & Metformin From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany) ClinicalTrials.gov · COMPLETED, 2019
